Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Royalty Pharma Expects To Deliver Portfolio Receipts For FY23 Of Approximately $3.05B, Which Includes A $50M Payment Related To Oral Zavegepant And Exceeds The Upper End Of Its Previous Guidance Range Of $2.95B-$3B

Author: Benzinga Newsdesk | January 08, 2024 08:35am

Posted In: RPRX